The Alzheimer Society of Canada is looking for input from people living with Alzheimer’s disease or mild cognitive impairment (MCI) and their care partners. Health Canada wants to learn about experiences with the condition, the health-care system and treatments.
Health Canada is currently reviewing Leqembi (lecanemab) and donanemab – medications to treat early-stage Alzheimer’s disease and mild cognitive impairment. As a part of the drug approval process, input from those who may be qualified to receive the drug helps shed light on the impact that these medications have on those taking them and on those who support them. It’s important to have a clear picture of the impacts of Alzheimer’s disease and mild cognitive impairment. With the results of this survey, the Alzheimer Society of Canada will make a submission to this agency to ensure that the voices of people with lived experience are represented and considered during this review process.
Here is the link to the survey for people living with Alzheimer’s disease or mild cognitive impairment:
research.net/r/Iamapersonwithalzheimers
Here is the link to the survey for people who support those living with Alzheimer’s disease or mild cognitive impairment:
research.net/r/Iamacaregiver
The deadline to submit your survey response is July 31, 2024.
Writing about your experiences with dementia may be challenging. If you find that the questions are upsetting or stressful in any way, please contact us for support by calling 204-943-6622 (Winnipeg) / 1-800-378-6699 (Manitoba) or emailing alzmb@alzheimer.mb.ca.
If you have any questions about the survey, please contact publications@alzheimer.ca or call 1-800-616-8816 ext: 2973.